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Abstract
Background: The cell-penetrating peptide derived from the Human immunodeficiency virus-1
transactivator protein Tat possesses the capacity to promote the effective uptake of various cargo
molecules across the plasma membrane in vitro and in vivo. The objective of this study was to
characterize the uptake and delivery mechanisms of a novel streptavidin fusion construct, TAT47–
57-streptavidin (TAT-SA, 60 kD). SA represents a potentially useful TAT-fusion partner due to its
ability to perform as a versatile intracellular delivery vector for a wide array of biotinylated
molecules or cargoes.
Results: By confocal and immunoelectron microscopy the majority of internalized TAT-SA was
shown to accumulate in perinuclear vesicles in both cancer and non-cancer cell lines. The uptake
studies in living cells with various fluorescent endocytic markers and inhibiting agents suggested
that TAT-SA is internalized into cells efficiently, using both clathrin-mediated endocytosis and lipid-
raft-mediated macropinocytosis. When endosomal release of TAT-SA was enhanced through the
incorporation of a biotinylated, pH-responsive polymer poly(propylacrylic acid) (PPAA), nuclear
localization of TAT-SA and TAT-SA bound to biotin was markedly improved. Additionally, no
significant cytotoxicity was detected in the TAT-SA constructs.
Conclusion: This study demonstrates that TAT-SA-PPAA is a potential non-viral vector to be
utilized in protein therapeutics to deliver biotinylated molecules both into cytoplasm and nucleus
of human cells.
Background
Due to the limitations of current drug delivery systems,
which have been hampered by their inefficiencies in tra-
versing the cell membrane, there is a pressing need to
develop methods for increasing intracellular delivery of
protein-based cargoes. Over the past decade, numerous
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been proposed, including electroporation, microinjec-
tion, viral vectors, liposome encapsulation and receptor-
mediated endocytosis. These methods have, however,
been plagued by low delivery efficiencies and, to some
extent, increased cellular toxicity. Naturally occurring
short cell-penetrating peptides (CPPs) derived from viral,
insect or mammalian proteins, have attracted considera-
ble interest in the field of drug delivery for their ability to
direct cellular uptake through active transport mecha-
nisms. CPPs are oligopeptides, 11–30 amino acid residues
in length, that are capable of conferring their apparent
translocation activity to proteins and other macromolecu-
lar cargo to which they are linked [1]. In recent years, CPPs
have been studied extensively, both in vitro and in vivo, for
their ability to delivery an array of pharmalogically rele-
vant cargoes, such as antisense oligonucleotides, peptides,
proteins, plasmids, liposomes and nanometer-sized parti-
cles, with encouraging results [2]. Lately, CPPs have also
been used to treat preclinical models of human disease
[3,4].
One of the most well-studied and efficient cell penetrating
peptides is the 11-amino-acid peptide of the Human
immunodeficiency virus type 1 (HIV-1) Tat protein. This
basic region of Tat, containing amino acid residues 47–57
(YGRKKRRQRRR; TAT47–57) [1,5], is crucial for many key
functions of the protein, including interaction with the
transactivation-responsive region in viral mRNA [6],
nuclear localization [7]and most importantly, cellular
uptake [8,9]. TAT47–57 has been shown to direct the inter-
nalization of an extensive list of cargoes ranging from
small peptides [4] to proteins and polymers [3,10-12],
liposomes [13,14], phage vectors [15], plasmid DNAs
[16,17] and even nanoparticles [18]. Moreover, TAT47–57
has also been used in vivo to deliver biologically active β-
galactosidase into all tissues of the mouse, even the brain
[12].
A variety of internalization routes for the TAT47–57
sequence and TAT-mediated cargoes have been suggested.
In the study of Fittipaldi et al. (2003) and Ferrari et al.
(2003) Tat11EGFP and GST-Tat-eGFP proteins were
reported to internalize into cells via caveolae-mediated
endocytosis and transported further to the perinuclear
area via an actin cytoskeleton-mediated mechanism
[19,20]. Wadia et al. (2004) in turn showed the internali-
zation of the TAT-Cre protein into cells by lipid raft-
dependent macropinocytosis [21], and Richard et al.
(2005) suggested the uptake of the TAT peptide via clath-
rin-mediated endocytosis [22]. Recently, also Säälik et al.
(2004) demonstrated the uptake of biotinylated TAT,
detected with FITC-labeled avidin, via both clathrin-
dependent and clathrin-independent endocytosis [23].
Central to the use of TAT, however, is not only its ability
to deliver cargo to cells but, importantly, its non-cytotox-
icity and stable biological activity over long time periods
[5].
Core streptavidin (SA; 125–127 aa) from Streptomyces
avidinii has been used in many pharmalogical applica-
tions. The exact mechanism of its cellular uptake and
intracellular delivery is, however, not well known. The
internalization of SA has been suggested to occur via
receptor-mediated endocytosis, involving lysine residues
[24] and the RYD sequence (Arg-Tyr-Asp) [25]. In vivo, the
biodistribution of SA has been shown to exhibit slow
clearance from the bloodstream due to accumulation in
the kidney [26,27]. The present study was designed to
gain insight into the internalization of a novel TAT-
streptavidin (TAT-SA) construct [10] in human cells.
Additionally, the ability of TAT-SA as a transporter of
biotin and biotinylated molecules was examined. The
subcellular distribution of TAT-SA was altered by bioti-
nylated, pH-responsive polymer poly(propylacrylic acid)
(PPAA), which further promoted the endosomal release.
These studies provide insights into the mechanism of TAT-
SA uptake in cells and may have implications for the opti-
mal use of TAT-SA and PPAA for the intracellular delivery
of numerous biotinylated macromolecules.
Results
Characterization of TAT-SA constructs
The structure of TAT-streptavidin (TAT-SA) has been pre-
viously described [10] as a tetrameric fusion protein, in
which the TAT47–57 peptide has been attached to the N-ter-
minus of each streptavidin monomer. Biotins or bioti-
nylated molecules are located into binding pockets of SA.
In this study, the stability and biotin-binding ability of
TAT-SA were analyzed by sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and immuno-
blot analysis. Both constructs, TAT-SA and Alexa488-
labeled TAT-SA (TAT-SA-A488), retained their tetrameric
(60 kD) conformations in reducing conditions as either
apoform or bound to biotin. When samples were pre-
heated to 68°C, a minor proportion of TAT-SA or TAT-SA-
A488 were detected as monomeric (15 kD) or dimeric (30
kD) forms. Binding of biotin to TAT-SA, however, stabi-
lized the constructs at 68°C, since only tetrameric pro-
teins were detected (unpublished data). Importantly,
reducing conditions and preheatmeant to 37°C did not
change the tetrameric conformations of either TAT-SA or
TAT-SA bound to biotin (Additional file 1).
Microscopical analysis of TAT-SA and SA uptake
TAT-SA (2 μM) was shown to internalize into human epi-
thelial carcinoma (HeLa), human lung carcinoma (A549)
and human lung fibroblast (MRC-5) cell lines at 4 h post
transduction (Fig. 1A–C). In living HeLa cells TAT-SA-
A488 was observed to cross the cell membrane rapidly,Page 2 of 14
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copy. At later timepoints the majority of TAT-SA-A488 was
localized in vesicular compartments within the cyto-
plasm, and only few cells displayed detectable nuclear
accumulation at 4 h post transduction (Fig. 1D–E). Con-
trol studies in which cells were first transduced either with
TAT-SA-A488 or TAT-SA, fixed at 4 post transduction and
immunostained for SA confirmed that both studies in liv-
ing and fixed cells resulted in a similar subcellular locali-
zation. Additionally, in cells transduced with SA-A488 (2
μM) alone, the cellular uptake was reduced (Fig. 1G–H).
The role of TAT during the nuclear import of SA was con-
firmed by injecting TAT-SA-A488 or SA-A488 (~1.5 × 106
molecules/cell) directly into the cytosol of HeLa cells. At 4
h post injection the majority of TAT-SA-A488 was found
to accumulate in the nucleoplasm with only minor local-
ization in the cytoplasm. In the nucleus TAT-SA-A488 was
distributed evenly throughout the nucleoplasm without
accumulation into distinct subnuclear structures (Fig. 1F).
In contrast, SA-A488 was distributed randomly through-
out the cytoplasm but not in the nucleus (Fig. 1I).
To monitor further the internalization and intracellular
transport of TAT-SA and SA, transduced HeLa cells were
labeled with an antibody against SA and nanogold-immu-
nolabeling electron microscopy with a silver enhance-
ment technique was used. Intracellular TAT-SA, visualized
as small, intensely labeled, grainy spots was localized in
large intracellular vesicles near the cell surface or in endo-
cytic-like vesicles adjacent to the nuclear membrane at 4 h
p.t (Fig. 2A). At the same time a small proportion of TAT-
SA was observed in the cytosol and the nucleus of cells
(Fig. 2B). Interestingly, in the control experiments SA was
observed in smaller cytoplasmic vesicles without any
nuclear localization than in those displaying TAT-SA at 30
min to 4 h post transduction.
Endocytic entry pathways of TAT-SA
To study the potential role of caveolar endocytosis in the
uptake of TAT-SA, HeLa cells were transduced and immu-
nolabeled with caveolin-1 antibody. No colocalization of
TAT-SA-A488 and caveolin was, however, apparent at 15–
60 min post transduction. In addition, the internalization
of TAT-SA-A488 into living HeLa cells was not blocked in
the presence of the cholesterol-depleting agent β-methyl-
cyclodextrin, a known inhibitor of caveolae-mediated
endocytosis. Importantly, control studies with human
hepatoma (HepG2) cells, which do not express caveolins
endogenously, demonstrated the efficient internalization
of TAT-SA (unpublished data).
In order to characterize clathrin-dependent and clathrin-
independent endocytosis in the uptake of TAT-SA, AP180-
C plasmid encoding a dominant-negative form of AP180,
an inhibitor of clathrin-mediated endocytosis, was used
[28]. In HeLa cells overexpressing AP180-C, the internali-
zation of TAT-SA was reduced, but not completely inhib-
ited at 4 h post transduction (Fig. 3A), whereas the uptake
of a clathrin-mediated endocytotic marker, Transferrin
(Tf; 200 μg/ml), was markedly decreased. In the absence
of AP180-C plasmid, immunofluorescence studies
revealed slight colocalization of TAT-SA-A488 and an
early endosomal marker (rab5) at 15 min post transduc-
tion as well as of TAT-SA-A488 and a recycling endosomal
marker (rab11) at 30 min post transduction (unpublished
data). In addition, the lysosomal marker LAMP-2 showed
clear colocalization with TAT-SA-A488 at 2–4 h post trans-
duction (Fig. 3B).
The kinetics of TAT-SA translocation from the cell periph-
ery towards the nuclear periphery at different times was
monitored in living HeLa cells in the presence of the fluo-
rescent endocytic markers transferrin and dextran. Partial
colocalization of TAT-SA-A488 and TRITC-labeled Trans-
ferrin (TRITC-Tf) was observed first at 5 min post trans-
duction in close proximity to the cell membrane and later
at 15–30 min post transduction in perinuclear vesicles
(Fig. 4A). In order to examine the role of non-clathrin-
mediated endocytosis, a fluid-phase endosomal marker
TRITC-labeled Dextran (TRITC-Dextran; 10 MW, 250 μg/
ml), was used to monitor macropinocytic entry pathway.
As shown in Figures 4B, 4C and in Additional File 2,
extensive colocalization of TAT-SA-A488 and TRITC-Dex-
tran was observed at both 15 min and 4 h post transduc-
tion. Moreover, quantitative analysis of the confocal
images (n = 25–30) revealed an approximately 10-fold
higher colocalization between TAT-SA-A488 and TRITC-
Dextran (39.2% ± 3.8%) than TAT-SA-A488 and TRITC-Tf
(3.1% ± 0.4%) at 15 min post transduction (Fig 5A).
The uptake of TAT-SA was further examined in living HeLa
cells by quantitative image analysis (n = 25–30) in the
presence of different endocytic inhibitors. In comparison
to relative fluorescence intensity of untreated, transduced
control cells (1.0 ± 0.3; Fig. 5B) a microtubule-disrupting
drug, nocodazole, caused only a slight decrease (0.78 ±
0.3) of intracellular TAT-SA-A488. In cells treated with the
filamentous F-actin elongation inhibitor cytochalasin D,
affecting both macropinocytosis and clathrin-dependent
endocytosis, a clear decrease (0.22 ± 0.1) in the amount of
cytoplasmic TAT-SA was, however, measured. Further-
more, amiloride, an inhibitor of Na+/H+ exchange
required for macropinocytosis, displayed significantly
reduced (0.14 ± 0.1) amounts of TAT-SA uptake. Impor-
tantly, in control experiments extensive disruption of
microtubules or actin filaments was observed in cells
treated either with nocodazole or cytochalasin D and ami-
loride. Additionally, cytochalasin D and amiloride mark-
edly decreased the internalization of TRITC-Dextran in
living cells (unpublished data).Page 3 of 14
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biotin via the PPAA polymer
The streptavidin-biotin association is one of the strongest
known non-covalent interactions in nature. In order to
alter the subcellular distribution of TAT-SA, a bioti-
nylated, pH-responsive polymer poly(propylacrylic acid)
(PPAA; 4 μM) was complexed to TAT-SA (2 μM) to pro-
mote endosomal release. The 3D illustrations of live HeLa
Confocal microscopy analysis of intracellular distribution of TAT-SA or SA at 4 h post transduction or injectionFigure 1
Confocal microscopy analysis of intracellular distribution of TAT-SA or SA at 4 h post transduction or injec-
tion. (A-C) Human cancer cell lines (HeLa, A549) and a non-cancer cell line (MRC-5) were transduced with TAT-SA prior to 
PFA fixation, permeabilization with Triton-X and immunolabeling with rabbit SA Ab followed by Alexa-488-conjugated goat 
anti-rabbit IgG (green). (D-E) Living HeLa cells were transduced or (F) injected to the cytoplasm with TAT-SA-A488 (green), 
or (G-H) transduced or (I) injected with SA-A488 (green). Scale bars, 10 μm.Page 4 of 14
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PPAA was localized both in cytoplasmic vesicles and in
the nucleus at 4 h post transduction (Fig. 6A, Additional
file 3). Interestingly, TAT-SA was shown to accumulate
into distinct nuclear foci, suggesting interactions with sub-
nuclear components (Fig. 6A). Moreover, quantitative
analysis (n = 25–30) of the relative nuclear fluorescence
intensity demonstrated that PPAA induced over 2-fold
increase in the intranuclear TAT-SA-488 (1.0 ± 0.3) when
compared to TAT-SA-A488 transduced control cells (0.4 ±
0.1; Fig. 6B).
The ability of TAT-SA to act as an intracellular delivery vec-
tor by transporting biotin and biotinylated molecules into
cells was also examined by confocal microscopy. As
shown in the 3D illustration, TAT-SA-A488 (2 μM) and
Biotin-DY-633 (1–2 μM) accumulated in large intracellu-
lar vesicles near the nucleus (Fig. 7A). No nuclear localiza-
tion of TAT-SA was observed, however. Further
experiments demonstrated strong colocalization of the
TAT-SA-biotin complex and TRITC-Dextran in vesicles at
the nuclear periphery at 2 h and 4 h post transduction,
implying that most of the TAT-SA-biotin complexes were
unable to escape from the intracellular vesicles. When
endosomal releasing polymer PPAA was complexed with
TAT-SA bound biotin, however, a major subnuclear accu-
mulation was observed (Fig. 7B, Additional file 4).
Finally, cell viability experiments with MTT cell prolifera-
tion assay showed that TAT-SA (2 μM) was not cytotoxic
to HeLa cells at 4–72 h post transduction (Table 1). Also
no indication of a cytotoxic effect was observed in the
presence of TAT-SA-complexed, biotinylated PPAA (4 μM)
at 4–24 h post transduction and only a slight decrease in
cell viability was detected at 48 and 72 h post transduction
(94.0% ± 3.8% survival) compared to untransduced con-
trol cells (100.0% ± 3.3% survival).
Discussion
The cell membrane is a barrier to the intracellular delivery
of many pharmacologically important biological macro-
molecules. Several cell penetrating peptides have been
shown to possess the ability to direct cellular uptake,
including the HIV-1 TAT peptide. So far TAT has been
used for directing the intracellular uptake of various bio-
molecular cargoes. In this study, however, a novel strepta-
vidin fusion protein TAT-SA [10] was examined, which
enables the transport of biotinylated cargoes into cells.
The internalization of TAT-SA was characterized in both
human cancer (HeLa and A549) and non-cancer cell lines
(MRC-5) (Fig. 1A–E). The internalization of SA was a rel-
atively slow process in which detectable amounts of SA-
A488 were present in the cytoplasm but not the nucleus of
HeLa cells at 4 h post transduction (Fig. 1G–H). On the
contrary, TAT-SA displayed rapid and efficient internaliza-
tion in living HeLa cells starting at 5 min post transduc-
Localization of internalized TAT-SA in HeLa cells by immunoelectron microscopy at 4 h post transductionFigure 2
Localization of internalized TAT-SA in HeLa cells by immunoelectron microscopy at 4 h post transduction. 
Intracellular TAT-SA was detected with pre-embedding immunolabeling technique, in which anti-SA staining was followed by 
silver-enhanced nanogold and gold-toning treatments. Localization of SA was shown as dark spots (arrow heads) within (A) 
cytoplasmic vesicular structures and further (B) in the nucleus of cells (nu). Scale bars, 1 μm.Page 5 of 14
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cytoplasm after 15 min (Fig. 1A, 1D–E). At later time
points, confocal and EM imaging demonstrated that the
majority of TAT-SA was localized in the cytoplasmic vesi-
cles with trace amounts in the nucleus (Fig, 1D–E, Fig. 2A
and 2B). Previously, numerous possible internalization
routes for TAT have been proposed, such as lipid-raft-
mediated macropinocytosis [21], caveolae-mediated
endocytosis [19,20] and clathrin-independent and
dependent endocytosis [22,23]. However, the uptake
characteristics of the TAT peptide alone and of TAT-conju-
gated cargoes have been demonstrated to differ signifi-
cantly [1,4,22]. Furthermore, TAT-mediated
internalization process has proposed to be dependent on
the properties of the cargo molecule, TAT concentration
and cell line [1,29,30]. In our study, streptavidin (60 kD)
as a larger partner of the TAT-SA fusion construct (TAT47–
57-peptide, 11aa) is likely to affect the uptake and intrac-
ellular trafficking of the vector. Notably, we show here
that direct microinjection of high concentrations of TAT-
SA or SA into the cytoplasm resulted in efficient nuclear
uptake of TAT-SA but not SA (Fig. 1F and 1I). This verifies
previous findings that upon introduction into the cytosol,
the TAT peptide is capable of mediating the nuclear
import of its streptavidin fusion partner. Moreover, it is
known that positively charged molecules internalize the
cells efficiently. Consequently, taken to account that the
plain SA is negatively charged (theoretical pI 6.04) and
TAT-SA is positively charged (theoretical pI 9.92), TAT-SA
internalizes the cells more efficiently than SA. Taken
together, these data demonstrate that TAT-SA is efficiently
internalized into various human cells but that only a rela-
tively small proportion is further released into the cyto-
plasm and transported into the nucleus, most likely
reflecting the inability of TAT-SA to escape from endocytic
vesicles.
In order to use TAT-SA as a vector to deliver biotinylated
molecules into cells, the internalization and delivery
mechanisms of the construct have to be characterized in
vitro and in vivo. In recent years a number of studies have
suggested a variety of internalization routes for TAT pep-
Immunofluorescence microscopy studies of the cellular distribution of TAT-SAFigure 3
Immunofluorescence microscopy studies of the cellular distribution of TAT-SA. (A) HeLa cells were transfected 
with mutant AP180-C, a specific dominant-negative inhibitor of clathrin-mediated endocytosis, 24 h prior to transduction with 
TAT-SA-A488 (green) and clathrin-endocytosis marker TRITC-Transferrin (TRITC-Tf, red). Cells were fixed with PFA at 4 h 
post transduction, permeabilized with Triton-X and finally stained with antibody against myc-tagged AP180-C followed by an 
Alexa-633-conjugated anti-mouse antibody (purple). (B) The distribution of TAT-SA-A488 and lysosomal marker (red) was 
monitored in HeLa cells fixed (PFA) at 4 h post transduction and stained with an antibody against lysosomal marker LAMP-2 
followed by an Alexa-546-conjugated anti-mouse antibody (red). Scale bars, 10 μm.Page 6 of 14
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endocytic pathways involving caveolae, lipid rafts and
clathrin-coated pits were analyzed using specific endo-
cytic markers, inhibition agents and immunofluorescence
labelings of each pathway. Previous studies have sug-
gested the TAT peptide enters cells by temperature-
dependent, caveolae-mediated endocytosis [19,20]. How-
ever, no evidence for the use of the caveolae route in the
internalization of TAT-SA was observed in the present
confocal microscopial colocalization studies with a cave-
olar marker protein. Moreover, treatment with methyl-β-
cyclodextrin, a cholesterol depletion agent known to
inhibit the caveolae route [31] or transduction of the cave-
olin-deficient HepG2 (unpublished data) and Jurkat T
cells [10,21,32,33] did not prevent the entry of TAT-SA-
A488 into living cells. Altogether, these data imply that
endosomal routes other than caveolae-mediated entry are
required for the uptake of TAT-SA.
It has been suggested that the internalization of SA occurs
via clathrin-mediated endocytosis [24,25]. Here, the role
of clathrin-dependent uptake of TAT-SA was monitored in
cells overexpressing the mutant AP180-C protein [34]. AP-
180C is required for the efficient assembly of clathrin-
coated pits by interacting with the clathrin heavy chain
through its C-terminal clathrin-binding motifs. Our data
indicated that in AP180 overexpressing cells the internali-
zation of TAT-SA was only slightly affected, whereas the
uptake of Tf, a marker of clathrin-dependent endocytosis
[35], markedly decreased (Fig. 3A). The double-immu-
Colocalization of TAT-SA with endocytic markers in living cellsFigure 4
Colocalization of TAT-SA with endocytic markers in living cells. (A) HeLa cells were transduced first with TAT-SA-
A488 (green) and then with TRITC-labeled transferrin (TRITC-Tf, red), a marker clathrin-mediated endocytosis, prior to anal-
ysis with confocal microscope at 15 min post transduction. (B) Cells transduced with TAT-SA-A488 and fluid-phase endosomal 
marker TRITC-labeled dextran (10 kD, red) were monitored at 15 min and (C) at 4 h post transduction. The white rectangles 
show the close-ups of representative structures. Scale bars, 10 μm.Page 7 of 14
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showed only minor colocalization of TAT-SA with early
and recycling endosomal markers at early time points
(unpublished data). However, at later stages of endocyto-
sis TAT-SA accumulated in lysosomes, the final destina-
tion of multiple endocytic pathways (Fig. 3B). Clathrin-
mediated endocytosis seemed therefore to be only par-
tially involved in the uptake of TAT-SA, the major inter-
nalization being mediated by another, more efficient
pathway.
Many oligoarginine peptides have been proposed as can-
didates for cellular internalization via macropinocytosis
[30]. Recently, uptake via clathrin-independent endocyto-
sis was also suggested in the internalization of TAT-Cre
and biotinylated TAT [21,23,36]. In our study, the intrac-
ellular localization of TAT-SA was monitored in living
HeLa cells with various fluorescent endocytic markers.
Shortly after internalization, only slight colocalization
was detected with TAT-SA and Tf, a clathrin-dependent
endocytic marker (Fig. 4A), whereas extensive colocaliza-
tion between TAT-SA and the fluid-phase endosomal and
macropinocytic marker dextran was observed (4B, 4C and
Additional file 2). Quantitative measurements of fluores-
cent intensity at 4 h post transduction displayed an
approximately 10-fold increase in the colocalization of
TAT-SA and dextran as compared to TAT-SA and Tf (Fig.
5A), thus supporting previous observations of the role of
macropinocytosis as an entry mechanism for TAT. Addi-
tionally, when cells were treated with amiloride, a known
inhibitor of macropinocytosis [37], the uptake of TAT-SA-
A488 was almost entirely inhibited. In the presence of
cytochalasin D, an F-actin-disrupting agent affecting both
macropinocytosis and clathrin-mediated endocytosis
[34,38], only a minor internalization of TAT-SA-A488
occurred (Fig. 5B). To conclude, we were able to establish
macropinocytosis as a major internalization pathway of
TAT-SA, as illustrated (Fig. 8).
Quantification of internalized TAT-SA in living HeLa cellsFigure 5
Quantification of internalized TAT-SA in living HeLa cells. (A) Quantitative analysis of the colocalization between 
both TAT-SA-A488 and TRITC-labeled transferrin and TRITC-labeled dextran (10 kD) at 15 min post transduction. (B) The 
relative fluorescence intensity of internalized TAT-SA-A488 was measured in cells treated with cytochalasin D (cytD), amilo-
ride (ami) or nocodazole (noco) at 4 h post transduction. Control cells (C) were untreated. The fluorescence intensity data 
was collected from multiple series of cells by confocal microcopy and processed with the 3D LSM program.Page 8 of 14
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ity of TAT-SA to act as a carrier of biotinylated molecules
into nucleus of human cells. Although numerous studies
have been conducted on TAT-related protein therapeutics,
only a few have attempted to address the intracellular
release of macromolecules from endocytic vesicles. Vari-
ous approaches for endosomal escape have been pro-
posed, such as endosome-disrupting agents (HA2, 43E),
acid-sensitive linkers or laser illumination [39]. In a recent
study by Wadia et al. (2004) it was shown that an internal-
ized TAT-Cre fusion protein was capable of nuclear uptake
and the subsequent induction of reporter gene expression.
Most of the TAT-Cre peptides were, however, observed to
reside in cytoplasmic vesicles and therefore the endo-
somal escape was enhanced by incorporation of the HA2
peptide from the influenza virus hemagglutin protein.
Albarran et al. (2005) have previously shown the delivery
of biologically active alkaline phosphatase (140 kD) and
R-phycoerythrin (240 kD) into the cytoplasm of Jurkat T
cells by TAT-SA. In present study, it was, however, shown
that both TAT-SA and TAT-SA bound to biotin remained
enclosed in endocytic vesicles for several hours after inter-
nalization (Fig. 4C, 7A, Additional file 3). Therefore, the
effect of a biotinylated pH-responsive polymer PPAA [10]
on the subcellular distribution of TAT-SA was investi-
gated. In previous studies PPAA has shown to disrupt
endosomes at pH 6.5 or below, causing the cytosolic
release of cargo molecules [10,40-43]. Recently, PPAA has
also been shown to enhance the delivery of antibody-tar-
geted conjugates into the cytoplasm [40] and PPAA-con-
taining lipoplexes have improved wound healing in mice
[42]. Our data indicated clearly that the nuclear import of
Effect of PPAA polymer on nuclear import of TAT-SA in HeLa cells at 4 h post transductionFigure 6
Effect of PPAA polymer on nuclear import of TAT-SA in HeLa cells at 4 h post transduction. (A) TAT-SA-A488 
was first pretreated with biotinylated, endosomal-releasing peptide PPAA and then transduced into cells. Cells were fixed with 
PFA, permeabilized with Triton-X and immunolabeled with rabbit anti-SA Ab followed by Alexa-488-conjugated goat anti-rab-
bit IgG (green) and embedded with DAPI-containing Mowiol-Dabco (nucleus, blue). Scale bar, 10 μm. (B) Quantitative analysis 
of the relative nuclear fluorescence intensity of TAT-SA-488 in living cells in presence or absence of PPAA. Multiple series of 
optical sections of the nuclear area were collected by confocal microscopy prior to processing the data with the 3D LSM pro-
gram.Page 9 of 14
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increased when combined with biotinylated PPAA (Fig.
6A and 7B, Additional file 4). Quantitative analysis of live
cells showed an approximately 2-fold increase in the
nuclear localization of TAT-SA-A488-PPAA complexes
compared to TAT-SA-A488 alone (Fig. 6B). The endo-
somal escape of TAT-SA-A488-PPAA may, however, been
more extensive, since the detection of fluorescence inten-
sity by confocal microscope is not sensitive enough to
observe all the nuclear fusion proteins. Importantly, no
significant cytotoxicity of TAT-SA-PPAA was observed by
MTT assay even at 72 h post transduction (Table 1). Over-
all, these data further demonstrate that the incorporation
of PPAA with TAT-SA alters the subcellular distribution of
the internalized fusion protein, resulting in improved
nuclear delivery of its biotin partner (Fig. 8).
Recently, several therapeutic applications for TAT-medi-
ated cellular internalization have been developed, includ-
ing the transport of an inhibitor for human
papillomavirus type 16 [44] and for the apoptosis-pro-
moting caspase-3 protein used in HIV-therapy [45], the
extension of the cytotoxic activity of herpes simplex virus-
1 thymidine kinase for cancer therapy [46], dendritic cell-
based immunotherapy [47] and enhancement of viral-
mediated gene delivery, [48] to name just a few. In this
study, the fusion of TAT with SA imparts the versatility
and precision of the SA-biotin system and allows the com-
plexation of numerous organic and inorganic cargoes.
Additionally, the TAT-SA fusion protein and its use in
combination with the endosomal-releasing polymer
PPAA demonstrates the potential of this construct for
delivering biotinylated molecules into various intracellu-
lar compartments, depending on the chemistry of the cho-
sen biotin partner.
Conclusion
Non-viral vector TAT-SA internalizes into human cells via
both macropinocytosis and clathrin-dependent endocyto-
sis. The subcellular distribution of TAT-SA is significantly
Table 1: Cytotoxicity Assay
p.t. Control TAT-SA TAT-SA-PPAA
24 h 100,0 ± 5,4 102, 5 ± 6,9 102,4 ± 1,6
48 h 100,0 ± 5,2 105,5 ± 5,7 96,4 ± 2,1
72 h 100,0 ± 3,3 99,0 ± 1,6 94,0 ± 3,8
MTT cytotoxicity assay of TAT-SA and TAT-SA-PPAA transduced HeLa cells at 24, 48 and 72 h post transduction. Survival percentages of three 
repetitive experiments and standard deviations are shown (control cells 100% survival).
Internalization and intracellular targeting of TAT-SA combined with biotin in HeLa cellsFigure 7
Internalization and intracellular targeting of TAT-SA combined with biotin in HeLa cells. (A) Cells were trans-
duced with the complex of TAT-SA-A488 (green) and biotin-DY-633 (purple), followed by TRITC-labeled dextran (10 kD, red) 
prior to live cell imaging at 4 h post transduction (B). Cells were transfected with TAT-SA complexed with biotinylated PPAA 
and biotin-DY-633. Cells were fixed with PFA, permeabilized with Triton-X and immunolabeled with rabbit anti-SA Ab fol-
lowed by Alexa-488-conjugated goat anti-rabbit IgG (green) and embedded with DAPI-containing Mowiol-Dabco (nucleus, 
blue). All images are 3D projections of the nuclear area. Scale bars 10 μm.Page 10 of 14
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mer PPAA. Here, we have characterized of a novel and ver-
satile vector that is capable of delivering an array of
biotinylated macromolecular cargoes into cells.
Methods
Cells
HeLa, A549, MRC-5 and HepG2 cell lines were obtained
from the American Type Culture Collection (ATCC, Man-
assas, VA). They were grown in monolayer cultures in Dul-
becco's modified Eagle's medium (DMEM, MEM),
supplemented with 10% inactivated fetal calf serum and
penicillin-streptomycin (Gibco BRL, Paisley, UK) at 37°C,
in 5% CO2. For HepG2 cells non-essential amino acids
(Gibco BRL) and Na-pyruvate (Merck & Co. Inc., White-
house Station, NJ) were also used.
Antibodies and other reagents
The rabbit polyclonal antibody against streptavidin was
the generous gift from Edward Bayer (The Weizmann
Institute of Science, Rehovot, Israel). The following poly-
clonal antibodies (Ab) and monoclonal antibodies
(MAb) were used to detect endocytic vesicles and cytoskel-
eton: rab5 MAb (Transduction Laboratories, Lexington,
KY); caveolin-1 MAb and Rab11 Ab (Zymed Laboratories,
South San Fransisco, CA); LAMP-2 MAb (Biotechnology
Associations Inc. Birmingham, AL); tubulin MAb and
actin Ab (Sigma Aldrich, St Louis, MO). The myc MAb
(9E10) was obtained from the ATCC. Anti-rabbit IgG AP-
conjugate was from Promega (Madison, WI). In the dou-
ble- and triple-immunolabeling studies Alexa-546- or
Alexa-633-conjugated anti-mouse antibodies and Alexa-
633-conjugated anti-rabbit antibodies were from Molecu-
lar Probes (Eugene, OR). Nanogold-conjugated polyclo-
nal rabbit immunoglobulin G (IgG) was purchased from
Nanoprobes (Yaphank, NY).
Streptavidin (SA), nocodazole, cytochalasin D, methyl-β-
cyclodextrin, amiloride and biotin were from Sigma.
TRITC-Dextran (10.000 MW) and TRITC-Tf were from
Molecular Probes. Biotin-DY-633 was obtained from
Dyomics GmbH (Jena, Germany). Biotinylated-PPAA
(poly(propyl-acrylic acid); 11 kD) was prepared as previ-
ously described [10,40,41,49]. Nanogold and HQ-silver
enhancement reagents were obtained from Nanoprobes.
Epon LX-112 was purchased from Ladd Research indus-
tries (Williston, VT).
TAT-Streptavidin (TAT-SA) construction and expression
The design and construction of the TAT-SA gene, T7
expression system (pET-21a, Novagen, Inc., Madison, WI)
and the isolation, refolding, purification as well as struc-
tural and preliminary functional characterization of the
TAT-SA fusion protein have previously been reported [10].
TAT-SA and SA was labeled with Alexa-488 according to
the protocol for amine-reactive probes (Molecular
Probes). The biotin-binding ability and stability of pro-
tein constructs were detected by SDS-PAGE and immuno-
blot analysis. In these experiments part of the samples
were first conjugated with biotin at RT for 15 min, and
then TAT-SA and biotinylated TAT-SA samples were pre-
heated to 22°C, 37°C or 68°C for 10 min. All samples
were predisposed to a reducing agent β-mercaptoethanol
for 30 min prior to loading.
Transduction of TAT-SA proteins
For the internalization studies cells were grown to subcon-
fluency on coverslips and entry of TAT-SA (2 μM) was
monitored in Hela, A549, MRC-5 and HepG2 cells fixed
at 4 h post transduction. Moreover, intracellular localiza-
tion of TAT-SA-A488 (2 μM) and SA-A488 (2 μM) was
analyzed in living HeLa cells at 4 h post transduction. For
Schematic model illustrating internalization of TAT-SA-PPAA in the human c llFigure 8
Schematic model illustrating internalization of TAT-
SA-PPAA in the human cell. After interaction with the 
cell surface, TAT-SA enters the cell via clathrin-mediated 
endocytosis or macropinocytosis (1), followed by transport 
to endosomal vesicles. Later, at low pH (≤6.5), PPAA induces 
the escape of TAT-SA from endosomes (2) and the nuclear 
localization sequence of the TAT peptides mediates the 
nuclear import of the construct (3). In the absence of PPAA 
polymer most of TAT-SA remains trapped in endosomes and 
is transported and further degraded in lysosomes.Page 11 of 14
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endocytic markers, HeLa cells were first transduced with
TAT-SA-A488 for 5 min, then fed with TRITC-labeled
Transferrin (TRITC-Tf, 200 μg/ml) or TRITC-labeled Dex-
tran (250 μg/ml) and finally monitored at different times
by confocal microscopy (Zeiss LSM 510 coupled to a Zeiss
Axiovert 100 M, Karl Zeiss, Jena, Germany). All live cell
imaging of the internalization process was monitored in
0.75-μm confocal sections, and summarized as 3 focal
plane images.
In the experiments with different endocytic inhibitors
HeLa cells were preincubated in medium containing
methyl-β-cyclodextrin (2.5 mM), nocodazole (60 μM),
cytochalasin D (4 μM) or amiloride (0.4 mM) for 30 min,
followed by TAT-SA-A488 transduction. All treatments
were maintained up to and including monitoring in living
cells. In control studies, the cells were fixed and depolym-
erization of microtubules or actin was verified by immu-
nolabeling of tubulin or actin.
To examine the intracellular distribution of TAT-SA with
biotin and the effect of the endosomal releasing polymer
PPAA, live cell studies were performed with TAT-SA and
fluorescent biotin and/or biotinylated-PPAA. TAT-SA-
A488 (2 μM) was incubated with Biotin-DY-633 (1–2
μM) and/or biotinylated-PPAA (4 μM) at room tempera-
ture (RT, 20–23°C) for 15–30 min, transduced into cells
at 37°C for 4 h and monitored in living or fixed HeLa
cells.
For live cell studies by a laser scanning confocal micro-
scope (Zeiss LSM 510) the cells were maintained in Scotch
chambers [50] in CO2-independent medium (Gibco) sup-
plemented with 10% inactivated FCS and penicillin-strep-
tomycin. Prior to detection the objective and sample
holder were heated to 37°C. In the imaging, appropriate
excitation and emission settings together with the multi-
tracking mode were used to avoid false colocalization.
To quantitate the colocalization of TAT-SA-A488 with
TRITC-Tf or TRITC-Dextran, the collected intracellular flu-
orescence intensity data for each cellular fluorescent
marker was processed using 3D LSM and ImageJ programs
(Colocalization Finder Plug-in). The influence of different
drugs on the cellular internalization of TAT-SA-488 was
quantitated by collecting the intracellular fluorescence
intensity data from multiple series of drug-treated cells
and then processed with the 3D LSM program. Quantita-
tive analysis corresponding to the nuclear import of TAT-
SA-488 in the presence of PPAA was performed by sum-
marizing the fluorescence intensity data from multiple
series of optical sections of the nuclear area and analyzing
with the 3D LSM program. Prior to all the quantitative
analyses the data from each channel were corrected by
reducing the background signal of untransduced cells.
For immunofluorescence microscopy, the cells were fixed
at set time intervals post transduction either with absolute
methanol (-20°C) at RT for 6 min or with 4% paraformal-
dehyde (PFA) in phosphate buffered saline (PBS, pH 7.4)
at RT for 20 min. PFA fixed cells were permeabilized with
0.5% Triton X-100. Cells were sequentially immunola-
beled with primary and labeled secondary antibodies,
embedded with Mowiol-DABCO or ProLong® Gold anti-
fade reagent with DAPI (Molecular Probes) and subjected
to confocal microscopy (Zeiss LSM 510 or Olympus Fluo-
View 1000, Olympus Optical Co., Tokyo, Japan).
Microinjection
Hela cells were grown to subconfluency on microgrid cov-
erslips (grid size, 175 nm; Eppendorf, Hamburg, Ger-
many). The injections were performed into the cytoplasm
of living cells using a semiautomatic system comprising a
Transjector 5246 and Micromanipulator 5171 (Eppen-
dorf) attached to an inverted microscope. Capillaries for
injections (Clark Electromedical Instruments, Pang-
bourne, UK) were prepared with a model P97 capillary
puller from Sutter Instruments (Novato, CA). The sample
ejection volume (0.1 pl) was measured by injecting radio-
active [3H]-biotin (Amersham Biosciences, Little Chal-
font, UK) standard. Since the concentration of injected
TAT-SA-A488 and SA-A488 was 1.4 mg/ml in PBS, the
actual intracellular amount of the injected proteins was
estimated to be approximately 1.5 × 106 molecules/cell.
Nanogold pre-embedding immunoelectron microscopy
After transduction of TAT-SA (5 μM) and fixing with glu-
taraldehyde, HeLa cells were washed with phosphate
buffer (0.1 M Na2HPO4 pH 7.4) and permeabilized with
a saponin buffer (0.01% saponin/0.1% BSA/0.1 M
Na2HPO4). Cells were then labeled with anti-SA Ab at RT
for 1 h, followed by nanogold-conjugated anti-rabbit IgG
at RT for 1 h. After appropriate washes with saponin and
phosphate buffers, post-fixing (1% glutaraldehyde in 0.1
M phosphate buffer) and quenching (50 mM NH4CL in
Na2HPO4) were performed. Moreover, silver enhance-
ment and gold toning (2% Na-acetate, 0.05% HAuCl4,
and 0.3% Na-thiosulphate in EM water) were followed by
post-fixing (1% osmium tetroxide, 0.1 M phosphate
buffer, K4Fe(CN)6 15 mg/ml) at 4°C for 1 h. The samples
were dehydrated in ethanol, stained with 2% uranylace-
tate, and embedded in LX-112 epon. Polymerization of
epon was performed over a 24 h period, first at 45°C and
then at 60°C, after which the samples were stained with
toluidine blue, cut with an ultramicrotom (Reichert-Jung,
Ultracut E) and stained again with uranylacetate and lead
citrate. Detection was performed by a JEOL JEM-1200EX
transmission electron microscope operated at ~60 kV.Page 12 of 14
(page number not for citation purposes)
BMC Biotechnology 2007, 7:1 http://www.biomedcentral.com/1472-6750/7/1Overexpression of the specific dominant-negative inhibitor 
of clathrin-mediated endocytosis
The AP180-C mutant construct was the generous gift of
Dieter Blaas (University of Vienna, Austria). Following the
manufacturer's protocol, HeLa cells were grown to 50%
confluency on coverslips and transfected by FuGENE 6
reagent (Roche, Basel, Switzerland) with Qiagen-purified
(Santa Clarita, CA) plasmid (2.5 μg/7 cm2 dish), encoding
for the myc-tagged assembly protein 180 (AP180-C). Two
days after transfection the cells were transduced with TAT-
SA-488 for 4 h at 37°C, fixed and immunolabeled with
the myc MAb as described above.
Cytotoxicity Assay
Cytotoxicity of TAT-SA (2 μM) and TAT-SA-PPAA (4 μM)
complexes were determined by CellTiter 96® Aqueous One
Solution Cell Proliferation Assay (MTT assay; Promega)
according to the manufacture's protocol. The measure-
ments were performed by a spectrophotometer (Wallac
Victor2 1420 Multilabel Counter and Wallac Workout™
data management software; Perkin Elmer Life Sciences,
Boston, MA) at an absorbance of 492 nm. Viability of cells
was calculated by comparison of the absorbance in con-
trol cells (100% survival) and TAT-SA or TAT-SA-PPAA
treated cells.
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